WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

Firm News

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a $45 million debt transaction with HealthCare Royalty Partners. The deal is meant to help fund an oncology pipeline for Curis.

The WilmerHale deal team that represented Curis included John Sigel and Eric French.

For more information read Curis' Fourth Quarter and Year-End Financial Results press release.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.